人民财讯2月27日电,默沙东2月26日宣布,其新型非核苷类巨细胞病毒(CMV)抑制剂普瑞明®(来特莫韦)三种剂型——来特莫韦片、来特莫韦注射液和来特莫韦片(II),已获得中国国家药品监督管理局(NMPA)批准,在有迟发性CMV感染和CMV病风险的6个月及以上且体重≥6kg的儿童患者中,可持续使用普瑞明®(来特莫韦)至HSCT后200天。
(文章来源:人民财讯)
人民财讯2月27日电,默沙东2月26日宣布,其新型非核苷类巨细胞病毒(CMV)抑制剂普瑞明®(来特莫韦)三种剂型——来特莫韦片、来特莫韦注射液和来特莫韦片(II),已获得中国国家药品监督管理局(NMPA)批准,在有迟发性CMV感染和CMV病风险的6个月及以上且体重≥6kg的儿童患者中,可持续使用普瑞明®(来特莫韦)至HSCT后200天。
(文章来源:人民财讯)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.